Determination of KRAS- and ERK-regulated phosphoproteomes in KRAS-mutant cancers

被引：0
|
作者：
Klomp, Jennifer E. [1 ]
Klomp, Jeff A. [1 ]
Diehl, Nathaniel J. [1 ]
Edwards, Cole A. [1 ]
Drizyte-Miller, Kristina [1 ]
Hibshman, Priya S. [1 ]
Yang, Runying [1 ]
Morales, Alexis J. [1 ]
Taylor, Khalilah E. [1 ]
Pierobon, Mariaelena [2 ]
Petricoin, Emanuel F., III [2 ]
Jared, Johnson L. [3 ]
Huntsman, Emily M. [3 ]
Yaron, Tomer M. [4 ]
Vaha-Koskela, Markus [5 ]
Herring, Laura E. [1 ]
Prevatte, Alex W. [1 ]
Barker, Natalie K. [1 ]
Graves, Lee M. [1 ]
Krister, Wennerberg [5 ]
Cantley, Lewis C. [3 ]
Christensen, James G. [6 ]
Cox, Adrienne D. [1 ]
Der, Channing J. [1 ]
Stalnecker, Clint A. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] George Mason Univ, Fairfax, VA USA
[3] Weill Cornell Med, New York, NY USA
[4] Columbia Univ, Vagelos Coll Physicians & Surg, New York, NY USA
[5] Univ Copenhagen, Copenhagen, Denmark
[6] Mirati Therapeut, San Diego, CA USA
来源：
MOLECULAR CANCER RESEARCH | 2023年 / 21卷 / 05期
关键词：
D O I：
10.1158/1557-3125.RAS23-B034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B034
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
    Hao, Huai-Xiang
    Wang, Hongyun
    Liu, Chen
    Kovats, Steven
    Velazquez, Roberto
    Lu, Hengyu
    Pant, Bhavesh
    Shirley, Matthew
    Meyer, Matthew J.
    Pu, Minying
    Lim, Joanne
    Fleming, Michael
    Alexander, Leigh Ann
    Farsidjani, Ali
    LaMarche, Matthew J.
    Moody, Susan
    Silver, Serena J.
    Caponigro, Giordano
    Stuart, Darrin D.
    Abrams, Tinya J.
    Hammerman, Peter S.
    Williams, Juliet
    Engelman, Jeffrey A.
    Goldoni, Silvia
    Mohseni, Morvarid
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12) : 2368 - 2380
  • [42] A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers
    Guerra, Stephanie L.
    Maertens, Ophelia
    Kuzmickas, Ryan
    De Raedt, Thomas
    Adeyemi, Richard O.
    Guild, Caroline J.
    Guillemette, Shawna
    Redig, Amanda J.
    Chambers, Emily S.
    Xu, Man
    Tiv, Hong
    Santagata, Sandro
    Janne, Pasi A.
    Elledge, Stephen J.
    Cichowski, Karen
    CANCER CELL, 2020, 37 (05) : 705 - +
  • [43] Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers
    Loi, Patrick
    Schade, Amy E.
    Rodriguez, Carrie L.
    Krishnan, Anjana
    Perurena, Naiara
    Nguyen, Van T. M.
    Xu, Yilin
    Watanabe, Marina
    Davis, Rachel A.
    Gardner, Alycia
    Pilla, Natalie F.
    Mattioli, Kaia
    Popow, Olesja
    Gunduz, Nuray
    Lannagan, Tamsin R. M.
    Fitzgerald, Samantha
    Sicinska, Ewa T.
    Lin, Jia-Ren
    Tan, William
    Brais, Lauren K.
    Haigis, Kevin M.
    Giannakis, Marios
    Ng, Kimmie
    Santagata, Sandro
    Helin, Kristian
    Sansom, Owen J.
    Cichowski, Karen
    CANCER DISCOVERY, 2024, 14 (12) : 2430 - 2449
  • [44] STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF innioitor by activating MEK/ERK signaling pathway
    Wang, Zhenlin
    Yin, Mengchen
    Chu, Peilin
    Lou, Meiqing
    AGING-US, 2019, 11 (17): : 7187 - 7196
  • [45] Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers
    Nussbaum, Daniel P.
    Martz, Colin A.
    Waters, Andrew M.
    Barrera, Alejandro
    Liu, Annie
    Rutter, Justine C.
    Cerda-Smith, Christian G.
    Stewart, Amy E.
    Wu, Chao
    Cakir, Merve
    Levandowski, Cecilia B.
    Kantrowitz, David E.
    Mccall, Shannon J.
    Pierobon, Mariaelena
    Petricoin III, Emanuel F.
    Joshua Smith, J.
    Reddy, Timothy E.
    Der, Channing J.
    Taatjes, Dylan J.
    Wood, Kris C.
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [46] Quantitative flux measurements of serum protein catabolism in PDAC and other KRAS-mutant cancers
    Nofal, Michel
    Zhang, Kevin
    Rabinowitz, Josh
    CANCER RESEARCH, 2015, 75
  • [47] Metabolic reprogramming in KRAS-mutant cancers: Proven targetable vulnerabilities and potential therapeutic strategies
    Wu, Ruilin
    Zhu, Hong
    He, Qiaojun
    Yuan, Tao
    Yang, Bo
    DRUG DISCOVERY TODAY, 2024, 29 (12)
  • [48] Molecular Pathways: The Basis for Rational Combination Using MEK Inhibitors in KRAS-Mutant Cancers
    Okumura, Shunsuke
    Jaenne, Pasi A.
    CLINICAL CANCER RESEARCH, 2014, 20 (16) : 4193 - 4199
  • [49] MicroRNA Expression in KRAS- and BRAF-mutated Colorectal Cancers
    Lundberg, Ida V.
    Wikberg, Maria L.
    Ljuslinder, Ingrid
    Li, Xingru
    Myte, Robin
    Zingmark, Carl
    Lofgren-Burstrom, Anna
    Edin, Sofia
    Palmqvist, Richard
    ANTICANCER RESEARCH, 2018, 38 (02) : 677 - 683
  • [50] Erratum: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
    Georgia Hatzivassiliou
    Jacob R. Haling
    Huifen Chen
    Kyung Song
    Steve Price
    Robert Heald
    Joanne F. M. Hewitt
    Mark Zak
    Ariana Peck
    Christine Orr
    Mark Merchant
    Klaus P. Hoeflich
    Jocelyn Chan
    Shiuh-Ming Luoh
    Daniel J. Anderson
    Mary J. C. Ludlam
    Christian Wiesmann
    Mark Ultsch
    Lori S. Friedman
    Shiva Malek
    Marcia Belvin
    Nature, 2013, 502 : 258 - 258
12345